Zacks Investment Research
10 Sept 2026, 22:50 UTC · 9h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
4 claims · each scored for market impact
Amgen's consensus revenue estimate for the upcoming quarter is $9.91 billion, a 3.68% increase year-over-year. — Positive revenue growth suggests business expansion, though the growth rate is modest.
+0.20Amgen's stock has declined by 5.99% over the past month, underperforming both the Medical sector and the S&P 500. — Consistent relative underperformance suggests negative momentum or specific headwinds for the name.
-0.20Amgen's expected EPS for the upcoming quarter is $5.69, representing a 0.89% increase over the previous year. — Flat earnings growth provides limited catalyst for price appreciation.
+0.10Amgen currently holds a Zacks Rank of #3 (Hold). — A 'Hold' rating indicates a neutral outlook with no strong signal to buy or sell.
Continue reading
5 related stories
Search tags
Which stocks this story touches
The stock recently declined by 2.25% in a session and 5.99% over the past month, lagging behind the broader market.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Seeking Alpha
2h ago
